Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Anke Steinmetz, François Vallée, Christian Beil, Christian Lange, Nicolas Baurin, Jochen Beninga, Cécile Capdevila, Carsten Corvey, Alain Dupuy, Paul Ferrari, Alexey Rak, Peter Wonerow, Jochen Kruip, Vincent Mikol & Ercole Rao. (2016) CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. mAbs 8:5, pages 867-878.
Read now
Read now
Umberto Leone Roberti Maggiore, Filippo Bellati, Ilary Ruscito, Maria Luisa Gasparri, Franco Alessandri, Pier Luigi Venturini & Simone Ferrero. (2013) Monoclonal antibodies therapies for ovarian cancer. Expert Opinion on Biological Therapy 13:5, pages 739-764.
Read now
Read now
Articles from other publishers (38)
Akira Saito, Joji Kitayama, Ryozo Nagai & Kenichi Aizawa. (2023) Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review. Pharmaceutics 15:6, pages 1664.
Crossref
Crossref
Elmira Karami, Parisa Azizi, Mahdi Behdani & Fatemeh Kazemi-Lomedasht. (2023) Efficient Inhibition of Pathologic Angiogenesis using Combination Therapy of
Anti-Epcam and Anti-VEGFR2 Nanobodies. Current Pharmaceutical Design 29:13, pages 1059-1066.
Crossref
Crossref
Shun-ichiro Komatsu, Yoko Kayukawa, Yoko Miyazaki, Akihisa Kaneko, Hisashi Ikegami, Takahiro Ishiguro, Mikiko Nakamura, Werner Frings, Natsuki Ono, Kiyoaki Sakata, Toshihiko Fujii, Shohei Kishishita, Takehisa Kitazawa, Mika Endo & Yuji Sano. (2022) Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial. Scientific Reports 12:1.
Crossref
Crossref
Vahideh Tarhriz, Mojgan Bandehpour, Siavoush Dastmalchi, Elaheh Ouladsahebmadarek, Habib Zarredar & Shirin Eyvazi. (2018) Overview of CD24 as a new molecular marker in ovarian cancer. Journal of Cellular Physiology 234:3, pages 2134-2142.
Crossref
Crossref
Shixue Chen, Lingling Li, Fan Zhang, Yu Wang, Yi Hu & Lei Zhao. (2019) Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy. Journal of Immunology Research 2019, pages 1-13.
Crossref
Crossref
F. Gueneau, U. Ravn & N. Fischer. (2019) Round optimization for improved discovery of native bispecific antibodies. Methods 154, pages 51-59.
Crossref
Crossref
Lucyna Kapka‑Skrzypczak, Sylwia Popek, Krzysztof Sawicki, Bartłomiej Drop, Magdalena Czajka, Barbara Jodłowska‑Jędrych, Magdalena Matysiak‑Kucharek, Dominika Furman‑Toczek, Martyna Zag�rska‑Dziok & Marcin Kruszewski. (2019) IL‑6 prevents CXCL8‑induced stimulation of EpCAM expression in ovarian cancer cells. Molecular Medicine Reports.
Crossref
Crossref
Wilhem Leconet, He Liu, Ming Guo, Sophie Le Lamer-Déchamps, Charlotte Molinier, Sae Kim, Tjasa Vrlinic, Murielle Oster, Fang Liu, Vicente Navarro, Jaspreet S. Batra, Adolfo Lopez Noriega, Sylvestre Grizot & Neil H. Bander. (2018) Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation. Molecular Cancer Therapeutics 17:9, pages 1927-1940.
Crossref
Crossref
Joji Kitayama, Hironori Ishigami, Hironori Yamaguchi, Yasunaru Sakuma, Hisanaga Horie, Yoshinori Hosoya, Alan Kawarai Lefor & Naohiro Sata. (2018) Treatment of patients with peritoneal metastases from gastric cancer. Annals of Gastroenterological Surgery 2:2, pages 116-123.
Crossref
Crossref
Ninad Katdare, Robin Prabhu & Aditi Bhatt. 2018. Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond. Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond
527
559
.
Aditi Bhatt & Akash Mehta. 2018. Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond. Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond
469
506
.
Abbas Alibakhshi, Fatemeh Abarghooi Kahaki, Shahrzad Ahangarzadeh, Hajar Yaghoobi, Fatemeh Yarian, Roghaye Arezumand, Javad Ranjbari, Ahad Mokhtarzadeh & Miguel de la Guardia. (2017) Targeted cancer therapy through antibody fragments-decorated nanomedicines. Journal of Controlled Release 268, pages 323-334.
Crossref
Crossref
SHIN YOUNG PARK, JUN SANG BAE, EUN JUNG CHA, HYUN HEE CHU, JANG SIHN SOHN & WOO SUNG MOON. (2016) Nuclear EpICD expression and its role in hepatocellular carcinoma. Oncology Reports 36:1, pages 197-204.
Crossref
Crossref
Shuhuan Hu, Guangyu Liu, Weiqiang Chen, Xiang Li, Wei Lu, Raymond H. W. Lam & Jianping Fu. (2016) Multiparametric Biomechanical and Biochemical Phenotypic Profiling of Single Cancer Cells Using an Elasticity Microcytometer. Small 12:17, pages 2300-2311.
Crossref
Crossref
Priyanka Bhatt, Imran Vhora, Sushilkumar Patil, Jitendra Amrutiya, Chandrali Bhattacharya, Ambikanandan Misra & Rajashree Mashru. (2016) Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of Controlled Release 226, pages 148-167.
Crossref
Crossref
Elisa Roca, Romaric Lacroix, Coralie Judicone, Sophie Laroumagne, Stéphane Robert, Sylvie Cointe, Alexandre Muller, Elise Kaspi, Patrice Roll, Alain R. Brisson, Claudio Tantucci, Philippe Astoul & Françoise Dignat-George. (2015) Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions. Oncotarget 7:3, pages 3357-3366.
Crossref
Crossref
Nobuaki Takahashi, Rinpei Niwa, Ryousuke Nakano & Kazuma Tomizuka. (2016) Strategy for technology development of antibody therapeutics. Folia Pharmacologica Japonica 147:4, pages 235-240.
Crossref
Crossref
C. F. Jehn, S. Küpferling, G. Oskay-Özcelik & D. Lüftner. (2014) A survey of treatment approaches of malignant ascites in Germany and Austria. Supportive Care in Cancer 23:7, pages 2073-2078.
Crossref
Crossref
Rinpei Niwa & Mitsuo Satoh. (2015) The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology. Journal of Pharmaceutical Sciences 104:3, pages 930-941.
Crossref
Crossref
Minghua Lv, Feng Qiu, Tingting Li, Yuanjie Sun, Chunmei Zhang, Ping Zhu, Xiaokun Qi, Jun Wan, Kun Yang & Kui Zhang. (2015) Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM. Mediators of Inflammation 2015, pages 1-11.
Crossref
Crossref
Shigenobu Emoto, Eiji Sunami, Hironori Yamaguchi, Soichiro Ishihara, Joji Kitayama & Toshiaki Watanabe. (2014) Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. Surgery Today 44:12, pages 2209-2220.
Crossref
Crossref
Joji Kitayama. (2014) Intraperitoneal chemotherapy against peritoneal carcinomatosis. Surgical Oncology 23:2, pages 99-106.
Crossref
Crossref
Suneetha Nunna, Richard Reinhardt, Sergey Ragozin & Albert Jeltsch. (2014) Targeted Methylation of the Epithelial Cell Adhesion Molecule (EpCAM) Promoter to Silence Its Expression in Ovarian Cancer Cells. PLoS ONE 9:1, pages e87703.
Crossref
Crossref
Jungyeob Seoung, Young-Han Park, Chaechun Rhim & Sungju Kim. (2014) Current Possible Drug Therapies for Ovarian Cancer. Journal of Cancer Therapy 05:13, pages 1203-1214.
Crossref
Crossref
Brian D. Harms, Jeffrey D. Kearns, Sergio Iadevaia & Alexey A. Lugovskoy. (2014) Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods 65:1, pages 95-104.
Crossref
Crossref
Agnieszka Martowicz, Johannes Rainer, Julien Lelong, Gilbert Spizzo, Guenther Gastl & Gerold Untergasser. (2013) EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth. Molecular Cancer 12:1.
Crossref
Crossref
Darrell J. Irvine, Xingfang Su & Brandon Kwong. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
48
.
Stefan R. Schmidt. 2013. Fusion Protein Technologies for Biopharmaceuticals. Fusion Protein Technologies for Biopharmaceuticals
1
24
.
Sarantos Kyriakopoulos & Cleo Kontoravdi. (2013) Analysis of the landscape of biologically-derived pharmaceuticals in Europe: Dominant production systems, molecule types on the rise and approval trends. European Journal of Pharmaceutical Sciences 48:3, pages 428-441.
Crossref
Crossref
John G. Elvin, Ruairidh G. Couston & Christopher F. van der Walle. (2013) Therapeutic antibodies: Market considerations, disease targets and bioprocessing. International Journal of Pharmaceutics 440:1, pages 83-98.
Crossref
Crossref
Agnieszka Martowicz, Gilbert Spizzo, Guenther Gastl & Gerold Untergasser. (2012) Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 12:1.
Crossref
Crossref
Fabrice Le Gall, Uwe Reusch, Anastasia Y. Bakulina & Sergej M. Kiprijanov. (2012) WITHDRAWN: Tetravalent Bispecific Single-Chain Fv Antibodies for Lysis of Leukemia Cells by Autologous T Cells. Journal of Molecular Biology.
Crossref
Crossref
James E. Frampton. (2012) Catumaxomab. Drugs 72:10, pages 1399-1410.
Crossref
Crossref
A. Stange. (2012) Malignant ascites – current treatment and novel therapeutic options. memo - Magazine of European Medical Oncology 5:1, pages 43-46.
Crossref
Crossref
György BerencsiIIIIII & Katalin N. Szomor. 2012. Maternal Fetal Transmission of Human Viruses and their Influence on Tumorigenesis. Maternal Fetal Transmission of Human Viruses and their Influence on Tumorigenesis
281
333
.
Sergej M. Kiprijanov. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology
441
482
.
B T F van der Gun, M L de Groote, H G Kazemier, A J Arendzen, P Terpstra, M H J Ruiters, P M J McLaughlin & M G Rots. (2011) Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer. British Journal of Cancer 105:2, pages 312-319.
Crossref
Crossref
B. T. F. van der Gun, L. J. Melchers, M. H. J. Ruiters, L. F. M. H. de Leij, P. M. J. McLaughlin & M. G. Rots. (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31:11, pages 1913-1921.
Crossref
Crossref